Seek Returns

ICLR vs. SMMT: ICON vs. Summit Therapeutics Stock Comparison

How do ICON (ICLR) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while SMMT is classified in Biotechnology.

Company profile comparison for ICON (ICLR) and Summit Therapeutics (SMMT)
Profile ItemICLRSMMT
NameICON plcSummit Therapeutics Inc.
Country/RegionIrelandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization15.34 billion USD13.06 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 15, 1998March 5, 2015
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ICLR
SMMT
GSPC
Loading price history…
ICON (ICLR) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Total Return (1Y)30.55%-2.48%
Total Return (3Y, Annualized)-6.05%116.18%
Total Return (5Y, Annualized)-5.40%26.89%

Risk Profile

Drawdown History

ICLR
SMMT
GSPC
Loading price history…
ICON (ICLR) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. ICON (ICLR) has a non-negative beta of 1.17.

Risk profile metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Volatility (1Y, Annualized)68.62%75.06%
Beta (5Y)1.17-1.51
Max Drawdown (5Y)-76.87%-87.64%
Avg. Volume (3M)943.50K6.19M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Sharpe Ratio (1Y)0.38-0.09
Sortino Ratio (1Y)0.52-0.13

Profitability

ROE (TTM)

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
SMMT
-220.01%
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

ICON (ICLR) at 5.26% retains a top-quartile share of revenue as profit, ahead of Summit Therapeutics (SMMT) at 0.00%, which keeps about the industry-typical share.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
SMMT
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both ICON (ICLR) at 10.73% and Summit Therapeutics (SMMT) at 0.00% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
SMMT
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
ROE (TTM)4.70%-220.01%
ROA (TTM)0.85%-111.99%
Net Margin (TTM)5.26%0.00%
Operating Margin (TTM)10.73%0.00%
Gross Margin (TTM)23.44%0.00%

Growth

Revenue Growth

Only one side can be read here: ICON (ICLR) reports revenue growth of 0.76%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Revenue Growth (YoY)0.76%--
Revenue Growth (3Y CAGR)2.15%--
EPS Growth (YoY)-71.56%--
EPS Growth (3Y CAGR)-23.82%--

Financial Strength

Current Ratio (MRQ)

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max
25.13
Q3
12.13
SMMT
5.99
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both ICON (ICLR) at 0.38 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
1.42
Q3
0.65
Median
0.15
SMMT
0.04
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Current Ratio (MRQ)1.325.99
Debt / Equity (MRQ)0.380.04
Net Debt / EBITDA5.55--

Dividends

Dividend Yield (TTM)

Neither ICON (ICLR) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither ICON (ICLR) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
SMMT
--
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): SMMT does not report P/E ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for ICON (ICLR), whose P/S ratio of 1.86 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
SMMT
--
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile relative to book while Summit Therapeutics (SMMT) at 23.13 prices above its industry range — a wide valuation gap against assets.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT
23.13
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and Summit Therapeutics (SMMT)
MetricICLRSMMT
P/E Ratio (TTM)81.90--
P/S Ratio (TTM)1.86--
P/B Ratio (MRQ)1.6823.13
Free Cash Flow Yield (TTM)3.51%-1.64%